Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Weight loss medications such as Wegovy and Zepbound have garnered an enormous amount of attention recently for their ability to help some users lose significant amounts of weight relatively easily.

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

When Eli Lilly reports its financial results early Thursday, investors will be looking for the company to press its advantage ...

Wegovy and Zepbound - except the weight regain is worse, because of the extreme way in which these medications suppress your ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying ...